Raise closed, search for fresh raises on Seedstage

Manchester, CT

Revolutionizing biopharma manufacturing with scalable, automated solutions for nanoparticle-based therapies.

• Innovative Manufacturing: Continuous and automated platform reduces production steps by up to 70%.
• Market Demand: Addresses increasing need for advanced drug delivery systems like mRNA and gene therapies.
• Proven Success: Over $3.2M in revenue since 2021, with adoption by the FDA and global biopharma partners.
• Sustainability Focus: Reduces waste and operational costs while enhancing scalability and efficiency.
• Comprehensive Support: Offers contract development, maintenance services, and consumable product lines.

Diant Pharma Inc. is raising funds to advance its continuous and automated manufacturing platform for nanoparticle-based therapies, including mRNA vaccines and cell and gene therapies. The company’s proprietary technology integrates multiple unit operations into a seamless process, reducing production steps and operational costs while enhancing scalability and precision. This innovation aims to address growing challenges in biopharma manufacturing, such as inefficiencies in traditional batch processes and increasing global demand for advanced drug delivery systems.

Leveraging its FDA-adopted platform and $3.2M+ in revenue since 2021, Diant Pharma is positioned to redefine the production landscape for high-cost therapeutics. With a focus on sustainability and automation, the company supports biopharma partners through contract development services, maintenance agreements, and consumable product lines. This funding will enable Diant Pharma to expand its global reach and continue delivering cutting-edge solutions for critical therapies.

Company Info

Diant Pharma develops advanced nanotherapy manufacturing technology, providing scalable, automated solutions for producing nanoparticles used in mRNA vaccines and gene therapies.

Diant Pharma Inc. specializes in advanced nanotherapy manufacturing, integrating multiple unit operations into a continuous and automated process for producing nanoparticles used in mRNA vaccines, gene therapies, and other medical applications. Their proprietary technology enhances precision and scalability while reducing production steps by up to 70%, offering significant cost savings and environmental benefits. Diant Pharma also provides contract development services to help biotech companies optimize and scale their production processes. The company’s innovative platform integrates downstream processing, in-line monitoring, and automation, ensuring high-quality nanoparticle manufacturing from discovery to commercial scale.

Positioned in the rapidly expanding biopharma market, Diant Pharma has generated over $3.2 million in revenue since 2021 and established partnerships with industry leaders. The company’s solutions address inefficiencies in traditional batch manufacturing, offering faster production and greater reliability to meet growing demand for advanced drug delivery systems. With a robust IP portfolio and FDA-recognized platform, Diant Pharma is well-positioned to capitalize on opportunities in the biopharma sector, including personalized medicine, cancer vaccines, and infectious disease therapies.